Alkem Laboratories Limited

rs,

10th August, 2023 To, The Corporate Relationship Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001. Scrip Code: 539523 National Stock Exchange of India Limited Excha

₹ 29,677 million

oday. Key highlights of Q1FY24 financial performance o o • Total Revenue from Operations was ₹ 29,677 million, year-on-year growth of 15.2% India sales were ₹ 19,007 million, year-on-year growth of 6.7% Inte

15.2%

l performance o o • Total Revenue from Operations was ₹ 29,677 million, year-on-year growth of 15.2% India sales were ₹ 19,007 million, year-on-year growth of 6.7% International sales were ₹ 10,146

₹ 19,007 million

Total Revenue from Operations was ₹ 29,677 million, year-on-year growth of 15.2% India sales were ₹ 19,007 million, year-on-year growth of 6.7% International sales were ₹ 10,146 million, year-on-year growth of 33.

6.7%

77 million, year-on-year growth of 15.2% India sales were ₹ 19,007 million, year-on-year growth of 6.7% International sales were ₹ 10,146 million, year-on-year growth of 33.4% • Earnings before Interes

₹ 10,146 million

of 15.2% India sales were ₹ 19,007 million, year-on-year growth of 6.7% International sales were ₹ 10,146 million, year-on-year growth of 33.4% • Earnings before Interest, Tax, Depreciation and Amortization (EBIT

33.4%

ion, year-on-year growth of 6.7% International sales were ₹ 10,146 million, year-on-year growth of 33.4% • Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) was ₹ 3,892 million, resu

₹ 3,892 million

n-year growth of 33.4% • Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) was ₹ 3,892 million, resulting in EBITDA margin of 13.1% vs. 7.9% in Q1FY23. EBITDA increased by 91.5% YoY • R&D exp

13.1%

st, Tax, Depreciation and Amortization (EBITDA) was ₹ 3,892 million, resulting in EBITDA margin of 13.1% vs. 7.9% in Q1FY23. EBITDA increased by 91.5% YoY • R&D expenses for the quarter was ₹ 1,202 mil

7.9%

epreciation and Amortization (EBITDA) was ₹ 3,892 million, resulting in EBITDA margin of 13.1% vs. 7.9% in Q1FY23. EBITDA increased by 91.5% YoY • R&D expenses for the quarter was ₹ 1,202 million, or

91.5%

was ₹ 3,892 million, resulting in EBITDA margin of 13.1% vs. 7.9% in Q1FY23. EBITDA increased by 91.5% YoY • R&D expenses for the quarter was ₹ 1,202 million, or 4.1% of total revenue from operations

₹ 1,202 million

in of 13.1% vs. 7.9% in Q1FY23. EBITDA increased by 91.5% YoY • R&D expenses for the quarter was ₹ 1,202 million, or 4.1% of total revenue from operations compared to ₹ 1,320 million in Q1FY23 at 5.1% of total r

Details of the conference call are as under

1

Dial in Details

1

Dial in Details

India : +91 22 6280 1149 / +91 22 7115 8050 International Toll Free USA UK Singapore Hong Kong : 1 866 746 2133 : 0 808 101 1573 : 800 101 2045 : 800 964 448 Express Join with Diamond Pass https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=9420919& linkSecurityString=33384ca691 You are requested to dial in 10 mins ahead of the scheduled start time. A transcript of this conference call will also be available on our website www.alkemlabs.com About Alkem Laboratories Ltd. Established in 1973 and headquartered in Mumbai, Alkem (NSE: ALKEM, BSE: 539523, Bloomberg: ALKEM.IN, Reuters: ALKE.NS) is a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The Company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals, which it markets in India and International markets. With a portfolio of more than 800 brands in